Johnson & Johnson (JNJD.XC)
Cboe UK - Cboe UK Real-time price. Currency in EUR
Add to watchlist
At close: 02:40PM BST
| Previous close | 135.68 |
| Open | 138.10 |
| Bid | 138.74 x 0 |
| Ask | 138.92 x 0 |
| Day's range | 137.92 - 138.10 |
| 52-week range | 133.12 - 158.80 |
| Volume | |
| Avg. volume | 22 |
| Market cap | 334.391B |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | 21.93 |
| EPS (TTM) | 6.29 |
| Earnings date | 17 Jul 2024 |
| Forward dividend & yield | 4.55 (3.30%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | N/A |
- Yahoo Finance Video
The 30-stock secret: ‘Don’t fight Papa Dow’
JC Parets, founder and chief strategist at All Star Charts, explains why fighting the Dow Breadth is futile and how embracing the approach can simplify your market analysis significantly. He spoke with Yahoo Finance’s Jared Blikre and Sydnee Fried on "Stocks in Translation." Listen to the full episode here, or wherever you get your podcasts. This post was written by Jared Blikre
ZacksJ&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
J&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
ZacksThe Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
Pfizer, Johnson & Johnson and Eli Lilly are part of the Zacks top Analyst Blog.
© 2024 Yahoo. All rights reserved.